Order Article Reprints

Chen X, Habib S, Alexandru M, Chauhan J, Evan T, Troka JM, Rahimi A, Esapa B, Tull TJ, Ng WZ, et al. Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma. Cancers. 2024; 16(19):3260. https://doi.org/10.3390/cancers16193260

Chen, Xinyi, Shabana Habib, Madalina Alexandru, Jitesh Chauhan, Theodore Evan, Joanna M. Troka, Avigail Rahimi, Benjamina Esapa, Thomas J. Tull, Wen Zhe Ng, and et al. 2024. "Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma" Cancers 16, no. 19: 3260. https://doi.org/10.3390/cancers16193260

Chen, X., Habib, S., Alexandru, M., Chauhan, J., Evan, T., Troka, J. M., Rahimi, A., Esapa, B., Tull, T. J., Ng, W. Z., Fitzpatrick, A., Wu, Y., Geh, J. L. C., Lloyd-Hughes, H., Palhares, L. C. G. F., Adams, R., Bax, H. J., Whittaker, S., Jacków-Malinowska, J., & Karagiannis, S. N. (2024). Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma. Cancers, 16(19), 3260. https://doi.org/10.3390/cancers16193260